Other Public Policy

OHE and Vifor Pharma present a poster at the last European Conference on Rare Diseases (ECRD) on the Mechanism of Coordinated Access to orphan medicinal products (MoCA) where evidence on avacopan for ANCA-associated vasculitis (AAV) was discussed using the Transparent Value Framework.

A new publication by Kourouklis and Gandjour (2022) investigates the impact of pharmaceutical spending on domestic early-stage pharmaceutical innovation in Europe. They find that European spending does impact the number of patent applications and that European pharmaceutical spending has an impact on European countries attracting early-stage development.

As US policymakers consider the potential implications of the drug pricing reforms contained within the Build Back Better Act, OHE releases a critique of the Congressional Budget Office scoring, demonstrating that the estimates are highly uncertain and policymakers should exercise caution when relying upon them.

US healthcare reform is frequently on the US presidential policy agenda.

Following the lead from his predecessors, President Obama’s controversial health insurance reform and President Trump’s public acknowledgement for the need for lower drug prices, President Biden has taken up the gauntlet and put the cost of prescription drugs front and centre.

Our new paper explores the evidence currently being used to allocate budgets between public sector activities in the UK and its limitations. We argue that there is much that can and should be done to improve the evidence base to inform the allocation of public sector budgets across portfolios. We propose a pragmatic approach to measure and value disparate public sector outputs in a commensurate manner.

A new paper, published last week in Applied Economics, by Dimitrios Kourouklis, Senior Economist at OHE, looks at the question of whether government funding increases public sector development of new medicines. Looking at public sector drug development in Europe, this paper suggests that government funding does have an impact on the research and development pipeline, particularly at the earlier stages of research for medicines targeting rare diseases.

OHE Lunchtime Seminar with Rafael Bengoa and David Hunter, 14th October 2019. The seminar will discuss policy-level enablers and barriers for implementing large-scale health systems reforms.

Professor Richard Frank will deliver the OHE Annual Lecture 2019 on Tuesday 15th October 2019 at The Royal Society, London.

A new paper by OHE and Health Education England on the value of international volunteers’ experience to the NHS has been published in Globalization and Heath.

‘Cascades of care’ have emerged as an attractive tool for assessing access to care for numerous chronic diseases. Dr Haacker will examine the use of cascades of care across diseases and populations, evaluate the use of cross-sectional targets in disease control strategies (e.g., the UNAIDS 90-90-90 targets), and address implications for cost-effectiveness analysis.

Pages

Subscribe to RSS - Other Public Policy